Fig
1. 100% x (1 – Kaplan and Meier probability estimates) of (A) prostate-specific
antigen (PSA) failure-free (P < .001) and (C) overall (P < .001) survival and
100% x (cumulative incidence probability estimates) of (B) prostate
cancer–specific mortality (P = .007) after external-beam radiation therapy (RT)
and androgen suppression therapy (AST) or RT in men with a pretreatment PSA
velocity more than 2 ng/mL/yr.
Journal of Clinical Oncology, Vol 24, No 25 (September 1), 2006: pp.
4190-4195
Six-Month Androgen Suppression Plus Radiation Therapy Compared With Radiation
Therapy Alone for Men With Prostate Cancer and a Rapidly Increasing Pretreatment
Prostate-Specific Antigen Level
Anthony V. D'Amico, Marian Loffredo, Andrew A. Renshaw, Brittany Loffredo, Ming-Hui
Chen
Fig
1. 100% x (1 – Kaplan and Meier probability estimates) of (A) prostate-specific
antigen (PSA) failure-free (P < .001) and (C) overall (P < .001) survival and
100% x (cumulative incidence probability estimates) of (B) prostate
cancer–specific mortality (P = .007) after external-beam radiation therapy (RT)
and androgen suppression therapy (AST) or RT in men with a pretreatment PSA
velocity more than 2 ng/mL/yr.